Does Rallies show Form 4 insider transactions for LUCD?

Yes. Rallies tracks LUCD insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.

Is LUCD research on Rallies investment advice?

No. Rallies provides research, data, and educational context for LUCD. It does not provide personalized investment advice.

LUCD (Lucid Diagnostics Inc. Common Stock) Stock Analysis - Insider Trades

Lucid Diagnostics Inc. Common Stock (LUCD) is a publicly traded Healthcare sector company. As of May 21, 2026, LUCD trades at $1.00 with a market cap of $182.19M and a P/E ratio of -1.46. LUCD moved +5.60% today. Year to date, LUCD is -11.50%; over the trailing twelve months it is -23.08%. Its 52-week range spans $0.75 to $1.80. Analyst consensus is strong buy with an average price target of $3.90. Rallies surfaces LUCD's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who is trading LUCD stock inside the company?

Recent LUCD insider activity includes Matheis Dennis bought 100.00K, Matheis Dennis bought 33.22K, Matheis Dennis bought 33.22K, Matheis Dennis bought 129.68K, and Matheis Dennis bought 129.68K. Rallies tracks insider transaction dates, shares, prices, and estimated values.

LUCD Key Metrics

Key financial metrics for LUCD
Metric	Value
Price	$1.00
Market Cap	$182.19M
P/E Ratio	-1.46
EPS	$-0.69
Dividend Yield	0.00%
52-Week High	$1.80
52-Week Low	$0.75
Volume	27
Avg Volume	0
Revenue (TTM)	$4.71M
Net Income	$-58.01M
Gross Margin	-41.73%

Recent LUCD Insider Trades

Matheis Dennis bought 100.00K (~$101.84K) on Aug 20, 2025.
Matheis Dennis bought 33.22K (~$43.79K) on May 22, 2025.
Matheis Dennis bought 33.22K (~$43.79K) on May 22, 2025.
Matheis Dennis bought 129.68K (~$171.52K) on May 21, 2025.
Matheis Dennis bought 129.68K (~$171.52K) on May 21, 2025.

Latest LUCD News

Lucid Diagnostics Posts $1.3M in Q1 EsoGuard Revenue, Secures $17M Offering — May 15, 2026
Lucid Diagnostics Exceeds Test Targets With 3,177 Tests, Raises $16.8M — May 14, 2026
Lucid Diagnostics Closes $18M Equity Offering with $15M Institutional Anchor — Apr 24, 2026
Lucid Diagnostics Posts $1.5M Q4 EsoGuard Revenue, Secures VA Contract — Mar 30, 2026

LUCD Analyst Consensus

5 analysts cover LUCD: 0 strong buy, 5 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $3.90.

Common questions about LUCD

Who is trading LUCD stock inside the company?: Recent LUCD insider activity includes Matheis Dennis bought 100.00K, Matheis Dennis bought 33.22K, Matheis Dennis bought 33.22K, Matheis Dennis bought 129.68K, and Matheis Dennis bought 129.68K. Rallies tracks insider transaction dates, shares, prices, and estimated values.
Does Rallies show Form 4 insider transactions for LUCD?: Yes. Rallies tracks LUCD insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.
Is LUCD research on Rallies investment advice?: No. Rallies provides research, data, and educational context for LUCD. It does not provide personalized investment advice.